BUSINESS

Takeda’s ALK Drug Alunbrig Earns EU Backing for 1st Line NSCLC

March 3, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Takeda Pharmaceutical said on March 2 that it has received the thumbs-up from a key European panel for approval of its ALK inhibitor Alunbrig (brigatinib) for the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC). The European Medicines Agency’s…

To read the full story

Takeda’s NSCLC Med Alunbrig Bags EU Nod for 1st-Line Use
April 8, 2020
Takeda’s ALK Drug Alunbrig Gets FDA’s Priority Status for Frontline NSCLC
February 26, 2020
Takeda’s ALK Drug Yield Positive Update in 1st Line NSCLC
November 26, 2019

BUSINESS

Half of Drug Makers Reluctantly Support G1 Rule Overhaul: Jiho Survey
March 12, 2026
FDA Resumes Review of Capricor/Nippon Shinyaku’s DMD Cell Therapy
March 12, 2026
Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…